| 前收市價 | 133.42 |
| 開市 | 133.82 |
| 買盤 | 125.80 x 100 |
| 賣出價 | 140.70 x 100 |
| 今日波幅 | 133.45 - 134.67 |
| 52 週波幅 | 111.83 - 141.16 |
| 成交量 | |
| 平均成交量 | 1,749,427 |
| 淨資產 | 6.99B |
| 每股資產淨值 | 133.37 |
| 市盈率 (最近 12 個月) | 17.41 |
| 收益率 | 0.32% |
| 年初至今每日總回報 | -1.70% |
| Beta 值 (5 年，每月) | 0.83 |
| 支出比率 (凈計) | 0.45% |
| 成立日期 | 2001-02-05 |
InvestorPlace3 Biotech ETFs Overdue for a Bounce
Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of course, to get a higher chance at outsized gains, one must also have a high risk tolerance and a long-enough investment horizon. Also, when the tides get rough, one needs the confidence and conviction to hang on (or buy on dips). Indeed, the turbulent seas of the higher-growth corners of the biotech
InvestorPlaceBiotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
If you’re looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ:IBB) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S. companies in the biotech industry. But that exchange traded fund (ETF) hasn’t done well in recent years. In the past three years, its total return was 0.95% in 2021, -13.69% in 2022 and 3.76% in 2023. Year-to-date (YTD), it’s up 2.91%, considerably less than the 8.74% for the SPDR S&P 500 ETF Trust (
InvestorPlaceUnder the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
In the fluctuating U.S. stock market, biotech stocks have faced challenges. The sector’s most popular index, iShares Biotechnology ETF (NASDAQ:IBB), is dropping 9% year to date (YTD). Nevertheless, recent market developments point to a rebound on the horizon. It’s compelling investors to re-evaluate and hunt for the top biotech stocks offering robust upside potential ahead. Federal Reserve Chairman Jerome Powell’s hinting at potential rate cuts could spell a significant relief rally for biotech
